This study examined how *C. albicans*-reactive Th17 cells are primed, distributed across mucosal sites, and functionally altered in patients with Crohn's disease, using antigen specificity mapping, TCR clonotype profiling, and tissue immunophenotyping.
*C. albicans*-specific Th17 cells targeted a narrow set of proteins enriched in fungal extracellular vesicles; at homeostasis they resided mainly in the oral mucosa, but shared TCR clonotypes were found across oral and gut tissues. In Crohn's disease patients, these cells were enriched in intestinal tissue, retaining their focused antigen specificity while acquiring pathogenic Th17 traits.
Human observational design limits causal inference; the study does not establish whether C. albicans-specific Th17 cells directly drive Crohn's disease pathology or are bystanders; sample size and composition of patient cohorts are not detailed in the abstract.
Clinicians managing Crohn's disease should be aware that *C. albicans*-specific Th17 cells — primed in the oral mucosa — may migrate to and become pathogenic in the inflamed gut, identifying them as a potential immunomodulatory target. Antifungal or mucosal immune strategies aimed at this cell subset may warrant investigation in IBD.
Explore related topics
